Kara Wools-Kaloustian

  • 2170 Citations
  • 24 h-Index
19932018

Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 11 Similar Profiles
HIV Medicine & Life Sciences
Kenya Medicine & Life Sciences
Eastern Africa Medicine & Life Sciences
Africa South of the Sahara Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Acquired Immunodeficiency Syndrome Medicine & Life Sciences
CD4 Lymphocyte Count Medicine & Life Sciences
Tuberculosis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Publications 1993 2018

  • 2170 Citations
  • 24 h-Index
  • 94 Article
  • 3 Conference contribution
  • 1 Chapter

Adherence to antiretroviral therapy in a clinical cohort of HIV-infected children in East Africa

Vreeman, R. C., Ayaya, S. O., Musick, B. S., Yiannoutsos, C. T., Cohen, C. R., Nash, D., Wabwire, D., Wools-Kaloustian, K. & Wiehe, S. E. Feb 1 2018 In : PLoS ONE. 13, 2, e0191848

Research output: Contribution to journalArticle

Eastern Africa
Pediatrics
HIV
therapeutics
Logistics
HIV
Confidence Intervals
Therapeutics
Guidelines
Central Africa

Increased prevalence of pregnancy and comparative risk of program attrition among individuals starting HIV treatment in East Africa

Holmes, C. B., Yiannoutsos, C. T., Elul, B., Bukusi, E., Ssali, J., Kambugu, A., Musick, B. S., Cohen, C., Williams, C., Diero, L., Padian, N. & Wools-Kaloustian, K. K. Jan 1 2018 In : PLoS ONE. 13, 1, e0190828

Research output: Contribution to journalArticle

Infectious Pregnancy Complications
patient compliance
Anti-HIV Agents
Eastern Africa
Patient Dropouts
2 Citations

Late Presentation with HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial

REALITY Trial Team Mar 4 2018 In : Clinical Infectious Diseases. 66, p. S140-S146

Research output: Contribution to journalArticle

Immunosuppression
HIV
Viruses
Phenotype
Mortality

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

Hakim, J. G. , Thompson, J. , Kityo, C. , Hoppe, A. , Kambugu, A. , van Oosterhout, J. J. , Lugemwa, A. , Siika, A. , Mwebaze, R. , Mweemba, A. , Abongomera, G. , Thomason, M. J. , Easterbrook, P. , Mugyenyi, P. , Walker, A. S. , Paton, N. I. , Agweng, E. , Awio, P. , Bakeinyaga, G. , Isabirye, C. & 31 others Kabuga, U., Kasuswa, S., Katuramu, M., Kiweewa, F., Kyomugisha, H., Lutalo, E., Mulima, D., Musana, H., Musitwa, G., Musiime, V., Ndigendawan, M., Namata, H., Nkalubo, J., Labejja, P. O., Okello, P., Olal, P., Pimundu, G., Segonga, P., Ssali, F., Tamale, Z., Tumukunde, D., Namala, W., Byaruhanga, R., Kayiwa, J., Tukamushaba, J., Abunyang, S., Eram, D., Denis, O., Lwalanda, R., Wools-Kaloustian, K. & Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team Jan 1 2018 In : The Lancet Infectious Diseases. 18, 1, p. 47-57 11 p.

Research output: Contribution to journalArticle

Lopinavir
Reverse Transcriptase Inhibitors
Protease Inhibitors
Nucleosides
Randomized Controlled Trials